Iressa Study in Patients With Salivary Gland Cancer

NCT00509002 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer

Interventions

DRUG: Gefitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]